Skip to main content
Clinical Trials/NCT04057677
NCT04057677
Terminated
N/A

Exercise Training as an Intervention to Improve Muscle Function and Recovery Following Bed Rest in Older Adults With Type 2 Diabetes

AdventHealth Translational Research Institute1 site in 1 country12 target enrollmentDecember 20, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Type 2 Diabetes
Sponsor
AdventHealth Translational Research Institute
Enrollment
12
Locations
1
Primary Endpoint
Leg Lean Mass
Status
Terminated
Last Updated
11 months ago

Overview

Brief Summary

The purpose of this research is to gather data on how exercise can help recovery of muscle mass, strength, and physical function after bedrest in older adults with pre-diabetes and type 2 diabetes.

Detailed Description

Older adults with type 2 diabetes (T2D) experience an accelerated rate of sarcopenia, which is the deterioration in muscle mass, strength, and physical performance. Periods of disuse caused by illness or hospitalization causes rapid loss of muscle mass and strength, which negatively impact physical function upon re-ambulation. Without adequate rehabilitation, physical function does not fully recover in older adults following disuse, reducing the quality of life and loss of independence. In this study, participants will enter a 10-day strictly controlled bed rest intervention at the Translational Research Institute (TRI) clinical research unit. Participants are randomized to either a progressive 4-week aerobic and resistance training recovery program at the exercise training or an ambulatory recovery group. The overall objective of this project is to determine how an exercise intervention can aid in recovery of muscle mass, strength and physical function following bed rest in older adults with pre-diabetes and T2D.

Registry
clinicaltrials.gov
Start Date
December 20, 2019
End Date
February 7, 2025
Last Updated
11 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
AdventHealth Translational Research Institute
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participant must be male or female, ages 60 through 80 years of age.
  • Participant has pre-diabetes or has been diagnosed with type 2 diabetes and taking 0-3 oral hypoglycemic agents, which include DPP-4 inhibitors, Sulfonylureas and/or Metformin therapy, and has an Hgb A1C \< 8.0%.
  • Participants on Insulin, injectable incretin mimetics, SGLT2 inhibitors, and Thiazolidinediones will be excluded.
  • Pre-Diabetics are defined as having an HgbA1c of greater than or equal to 5.7% and less 6.5%, or a fasting glucose of greater than or equal to 100 mg/dl and less than 126 mg/dl or has a glucose of greater than or equal to 140 mg/dl and less than 200mg/dl at the 2 hour blood draw during OGTT
  • Participant must have renal function with an estimated glomerular filtration rate (eGFR) \> 45 ml/min/1.73m2 determined at screening.
  • Participant's triglyceride level is \< 350 mg/dl and LDL cholesterol is ≤ 150 mg/dl at screening.
  • Participant states willingness to follow protocol as described, the prescribed activity level and completing any forms needed throughout the study.
  • Participant has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.

Exclusion Criteria

  • Participant has type 1 Diabetes.
  • BMI \> 40.0 kg/m2
  • Participant is actively pursuing weight loss and/or lifestyle changes.
  • Participant has a history of pressure ulcers.
  • Participant has a stated history of Deep Vein Thrombosis (DVT), pulmonary embolism, or a known hypercoagulable condition, or other clotting or bleeding disorders.
  • History of gastrointestinal or intracranial hemorrhage.
  • History of stroke or cerebrovascular accident.
  • Recent history of major trauma (within 3 months).
  • Thrombocytopenia (\<100,000/microL) or hyperkalemia (K \> 5.2) on screening laboratory assay. May repeat lab value per PI discretion.
  • Untreated or poorly controlled hypertension (SBP \> 150, DBP \> 95), or hypotension (SBP \<100 DBP \<60)

Outcomes

Primary Outcomes

Leg Lean Mass

Time Frame: Immediately following bed rest, and following the exercise or non-exercise recovery phase

Determined by DXA (dual energy x-ray absorptiometry)

Mitochondrial Respiration

Time Frame: mmediately following bed rest, and following the exercise or non-exercise recovery phase

Determined by high resolution respirometry in permeabilized muscle fiber bundles

Secondary Outcomes

  • Insulin Sensitivity(mmediately following bed rest, and following the exercise or non-exercise recovery phase)
  • Physical function(mmediately following bed rest, and following the exercise or non-exercise recovery phase)

Study Sites (1)

Loading locations...

Similar Trials